Surface Oncology announces anticipated near-term corporate milestones

In the first half of 2023, Surface expects to present updated clinical data from the ongoing Phase 2 trials investigating SRF388 in liver and lung cancer. Initial safety and efficacy data from the ongoing SRF114 Phase 1/2 clinical study are anticipated in 2024.